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Background: Insulin resistance (IR) is frequently associated with endothelial dysfunction and has been proposed to
play a major role in cardiovascular disease (CVD). On the other hand, obesity has long been related to IR and
increased CVD. However it is not known if IR is a necessary condition for endothelial dysfunction in human obesity,
allowing for preserved endothelial function in obese people when absent. Therefore, the purpose of the study was
to assess the relationship between IR and endothelial dysfunction in human obesity and the mechanisms involved.
Methods: Twenty non-insulin resistant morbid obese (NIR-MO), 32 insulin resistant morbid obese (IR-MO), and 12
healthy subjects were included. Serum concentrations of glucose, insulin, interleukin-6 (IL-6), tumor necrosis factor-
alpha (TNF-α), resistin and adiponectin were determined. IR was evaluated by HOMA-index. Endothelium-
dependent relaxation to bradykinin (BK) in mesenteric microvessels was assessed in wire myograph.
Results: Serum IL-6, and TNF-α levels were elevated only in IR-MO patients while resistin was elevated and
adiponectin reduced in all MO individuals. Mesenteric arteries from IR-MO, but not from NIR-MO subjects displayed
blunted relaxation to BK. Vasodilatation was improved in IR-MO arteries by the superoxide scavenger, superoxide
dismutase (SOD) or the mitochondrial-targeted SOD mimetic, mito-TEMPO. NADPH oxidase inhibitors (apocynin
and VAS2870) and the nitric oxide synthase (NOS) cofactor, tetrahydrobiopterin failed to modify BK-induced
vasodilatations. Superoxide generation was higher in vessels from IR-MO subjects and reduced by mito-TEMPO.
Blockade of TNF-α with infliximab, but not inhibition of inducible NOS or cyclooxygenase, improved endothelial
relaxation and decreased superoxide formation.
Conclusions: Endothelial dysfunction is observed in human morbid obesity only when insulin resistance is present.
Mechanisms involved include augmented mitochondrial superoxide generation, and increased systemic
inflammation mediated by TNF-α. These findings may explain the different vascular risk of healthy vs unhealthy
obesity.
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MitochondriaBackground
Obesity represents one of the main health problems in
modern societies, reaching epidemic proportions in de-
veloped countries [1]. Jointly to other consequences on
health, obesity is one of the leading risk factors for car-
diovascular disease (CVD). Endothelial dysfunction pre-
cedes in several years the clinical manifestations of CVD* Correspondence: leocadio.rodriguez@salud.madrid.org
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reproduction in any medium, provided the orbeing a key event in its development [2]. A growing
body of evidence reveals the presence of an altered
endothelial vascular function manifested by a reduction
in the endothelium-dependent vasodilatations in both
animal models of obesity [3] and human obese subjects
[4,5]. Frequently observed in obese patients, insulin re-
sistance appears among the different pathogenic mecha-
nisms leading to endothelial dysfunction. In fact, an
impairment of endothelial function associated to insulin
resistance has been documented in different vascular
districts [3,4,6,7].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ance and endothelial dysfunction in obese people
strongly suggests that these two usual features in the
obese phenotype are causally linked, there is no available
data in the literature directly addressing the implication
of insulin resistance in the pathogenesis of endothelial
dysfunction in human obesity. In fact studies showing
impaired endothelial function in obese people have been
carried out mainly by comparing endothelial function in
vessels from obese subjects (without establishing differ-
ences between those who are sensitive or resistant to in-
sulin action) to vessels from healthy adult subjects with
normal weight (with preserved endothelial function).
This is a key issue since clinical evidence suggests that
there is a significant proportion (~30%) of obese individ-
uals that are free from insulin resistance and does not
manifest the panoply of cardiovascular diseases (CVD)
usually observed in obese people [8]. This raises the hy-
pothesis of a preservation of endothelial function and,
consequently, vascular disease, when insulin resistance is
lacking. Taken together, all these observations point to
insulin-resistance as a major factor to explain the differ-
ence in CVD between both types of obese people.
Inflammation and reduced bioavailability of nitric
oxide (NO) due in part to increased oxidative stress
seem to play an outstanding role in the endothelial dys-
function associated to obesity [9,10]. Low-grade chronic
vascular inflammation has been suggested to be a key
event in the pathogenesis of endothelial dysfunction and
CVD. Increased plasma concentrations of interleukin-6
(IL-6) and other inflammatory cytokines have been asso-
ciated with the presence of endothelial dysfunction in
obese patients [11]. In addition, tumor necrosis factor-
alpha (TNF-α) and IL-6 levels have been shown to be in-
dependent predictors of coronary endothelial function
[12]. Furthermore, inflammation and oxidative stress are
intimately related processes. In fact, inflammatory cyto-
kines reduce NO-mediated responses by increasing re-
active oxygen species (ROS) production that results in
decreased NO availability [13]. However, once again, no
data is available in human vessels concerning the role of
inflammatory cytokines or the contribution of oxidative
stress to endothelial dysfunction in obese subjects with
respect to the presence or absence of insulin resistance.
Although strong evidences support the relationship
between insulin resistance and obesity as well as be-
tween insulin resistance and endothelial dysfunction,
studies analyzing the specific role of insulin resistance in
endothelial dysfunction associated to obesity are defin-
itely lacking. Therefore, the aim of the present study was
to determine the role of insulin resistance on endothelial
function in obesity as a marker of early vascular damage
that could provide a potential explanation for the differ-
ent vascular outcomes in these two largely recognizedsubtypes of human morbid obesity: healthy and unhealthy.
With this purpose we evaluated endothelial-dependent
vasodilation in mesenteric microvessels from morbid obese
individuals, with or without insulin-resistance, and the in-




The present study included 52 morbid obese (MO) sub-
jects with a body mass index (BMI) ≥ 40 kg/m2 aged
between 25 and 65 years, who underwent bariatric
surgery in the Hospital Universitario de Getafe with
mixed techniques combining Roux-en-Y gastric bypass, ver-
tical sleeve gastrectomy and adjustable gastric banding.
Subjects with history or clinical evidence of CVD (con-
gestive heart failure; cardiac and/or cerebrovascular is-
chemic disease) were excluded, but not those with
cardiovascular risk factors like hypertension, type 2
diabetes, or dyslipidemia. Subjects were characterized
as metabolic syndrome (MetS) if they met three of the
following National Cholesterol Education Program
Adult Treatment Panel III criteria as modified by the
American Diabetes Association.
Insulin resistance was estimated by calculating the val-
idated score for Homeostasis Model Assessment of Insu-
lin Resistance (HOMA-IR) [14]. MO subjects were
distributed into two groups depending on the HOMA-
IR: non-insulin resistant (NIR; HOMA IR< 3.8; n=20)
and insulin resistant (IR; HOMA-IR≥ 3.8; n=32). Cut-off
point was previously defined for a Spanish population
corresponding to the 90th percentile HOMA-IR value in
non-diabetic adult subjects [15].
Twelve healthy non-obese subjects were recruited, as
control group, among patients undergoing laparoscopic
surgery procedures in our hospital (hiatus hernia repair,
achalasia or cholecystectomies). Exclusion criteria for
this control group were: BMI≥ 30 kg/m2; current or
former smokers; hypertension (≥140/90 mmHg); dia-
betes; total cholesterol >200 mg/dl; history or clinical
evidence of cardiovascular disease and any other condi-
tion that might interfere with the progress of the study.
Written informed consent was obtained from the sub-
jects who participated in the study. The study was
approved by both the Ethics Committee and Research
Committee of the Hospital Universitario de Getafe.
Biochemical measurements
Blood samples were collected for measurement of serum
fasting glucose, glycosylated hemoglobin (HbA1C), serum
fasting insulin, serum lipid profile and C-reactive protein
(CRP) in the Laboratory of Clinical Analysis of our hos-
pital. HOMA-IR was calculated as described by Mathews
et al. [16].
El Assar et al. Journal of Translational Medicine 2013, 11:263 Page 3 of 11
http://www.translational-medicine.com/content/11/1/263Circulating levels of TNFα, IL-6, adiponectin (R&D
systems) and resistin (Bender MedSystems) were deter-
mined in serum by ELISA, following the manufacturer
instructions, in the Research Unit Laboratory. All sam-
ples were assessed in duplicate.Measurement of vascular reactivity in isolated vessels
Small arteries (200–500 μm, approximately 2 mm
length) were isolated from visceral fat obtained from
MO or control subjects during laparoscopic surgery.
The arteries were cleaned, and mounted as ring prepara-
tions on small vessel wire myographs, as described else-
where [17,18]. Resting tension for the experiments was
calculated to obtain an internal circumference equivalent
to 90% of the tension of the vessels when relaxed in situ
under a transmural pressure of 100 mmHg, using the
Myo-Norm-4 program (Cibertec, Madrid, Spain). The
vessels were contracted with K+125 mmol/l and the
segments failing to produce a tension equivalent to a
pressure of 100 mmHg were rejected. After a washout
period, the arteries were contracted again with 25
mmol/l K+, which produced approximately 80% of the
maximum response. When the contraction reached
a plateau, the endothelium-dependent relaxation was
assessed by adding increasing concentrations of bradyki-
nin (BK; 10 nmol/l to 3 μmol/l). Vasodilatory effects of
insulin (0.01 nmol/l to 3 μmol/l) were also evaluated.
Responses to sodium nitroprusside (SNP; 1 nmol/l to 300
μmol/l) were used to test non endothelium-dependent re-
laxant responses.
In some experiments, the microvascular mesenteric
segments were pretreated for 30 minutes before BK
administration with the superoxide scavenger, bovine
copper-zinc superoxide dismutase (SOD; 100 U/ml);
the mitochondrial-targeted antioxidant mito-TEMPO
(5 μmol/l); the NAD(P)H oxidase inhibitors, apocynin
(100 μmol/l) or VAS2870 (10 μmol/l); the NO synthase
(NOS) cofactor, tetrahydrobiopterin (BH4; 10 μmol/l); the
non-selective cyclooxygenase inhibitor, indomethacin
(10 μmol/l); the selective inducible NOS (iNOS) inhibitor,
1400 W (10 μmol/l); or the anti-TNFα monoclonal
antibody, infliximab (100 μmol/l, Schering-Plough
[Merck], Whitehouse Station, New Jersey). These experi-
ments were systematically performed in a paired way, with
parallel analysis of control and treated segments from the
same subjects.
The experiments were performed in Krebs Henseleit
solution (KHS), which was composed of (mmol/l): NaCl
115, CaCl2 2.5, KCl 4.6, KH2PO4 1.2, MgSO4.7H2O 1.2,
NaHCO3 25, glucose 11.1, and Na2EDTA 0.03. The solu-
tion was bubbled with a mixture of 95% O2 and 5% CO2
to maintain a pH of 7.4. Unless otherwise stated, all drugs
used were purchased from Sigma (St Louis, MO, USA).Human recombinant insulin (Humulin R) was obtained
from Eli Lilly, (Spain).
Detection of vascular superoxide anion generation in
microvessel segments
Formalin-fixed, paraffin-embedded transverse sections
(5 μm thick) were mounted on polylysine-coated glass
slides. The in situ production of superoxide anion was mea-
sured by means of the fluorescent dye dihydroethidium
(DHE) as described previously [18]. Briefly, mesenteric ar-
terial sections were incubated for 90 min at 37 °C with the
fluorescent probe DHE (4 μmol/l; Calbiochem, Darmstadt,
Germany). In the presence of superoxide anion, DHE is ox-
idized to ethidium that yields bright red fluorescence. After
washing with PBS plus 0.1% Triton X-100, sections were
mounted and visualized by fluorescence microscopy
(Olympus BX51, Japan). The percentage of nuclei showing
positive red signal with respect to total nuclei in ar-
terial wall was determined with imaging software
(McBiophotonics Image J, NIH, Bethesda, Maryland).
Statistical analysis
Categorical variables were analyzed by the Chi-square
test. Results from numerical variables were expressed as
mean±SEM. The number of subjects (N) and the num-
ber of vascular segments (n) used for relaxation curves
are indicated in each graph. Complete concentration-
response curves to BK or to SNP in vessels from the par-
ticipants were compared by a two-factors analysis of
variance (ANOVA). Comparison of pD2, (which is de-
fined as the negative logarithm of the concentration of
BK required to obtain 50% of maximal relaxation) for
each subject was statistically analyzed by a one-factor
ANOVA followed by a Student-Newmann-Keuls test.
This same analysis was also used to compare serum
cytokine determinations and DHE staining. Student t
test was used in all other comparisons. Pearson′s correl-
ation coefficient was used to assess correlation among
variables. Models of lineal regression were constructed,
with the pD2 considered as the dependent variable. In all
cases, a probability value of less than 5% was considered
significant. Data were analyzed using version 20.0 of
SPSS software (SPSS Corp, Chigaco, IL).
Results
Insulin resistant morbid obese (IR-MO) subjects when
compared to non insulin-resistant morbid obese (NIR-
MO) group showed significantly larger waist circumfer-
ence and higher levels of fasting insulin, HOMA-IR,
HbA1C and CRP, while HDL cholesterol levels were
lower (Table 1). In addition, the percentage of MetS was
significantly higher in IR-MO versus NIR-MO subjects.
Comorbid conditions and treatments received by the pa-
tients at the time of surgery are shown in Table 1.







Age (years) 42.9±2.9 42.3±1.7 0.837











Hypertension (%) 20.0 37.5 0.183
Dyslipidemia (%) 25.0 21.9 0.795






















HOMA-IR 2.3±0.1 7.3±0.8 <0.001











M= Male; F= Female; MetS= Metabolic syndrome; HDL= High-density
lipoprotein; LDL= Low-density lipoprotein; TC= Total cholesterol; HOMA-IR=
Homeostasis Model Assessment of Insulin Resistance; CRP= C-Reactive Protein.
Significant differences are highlighted in bold.
Table 2 Serum concentrations of biomarkers of

























IL-6 (pg/ml) 1.24±0.19 2.81±0.37 4.81
±0.78 ¶, ‡
TNF-α= Tumor necrosis factor alpha; IL-6= Interleukin 6. * p< 0.05; ¶ p< 0.01; †
p< 0.001 vs control subjects. ‡ p< 0.05 vs non-insulin resistant morbid
obese subjects.
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sue activity, TNF-α and IL-6 levels were increased in IR-
MO patients when compared to control subjects, while
there were no differences between NIR-MO and control
subjects (Table 2). Finally, the levels of adiponectin were
reduced and those of resistin increased, in both IR-MO
and NIR-MO patients (Table 2).Endothelial dysfunction is associated with insulin
resistance in morbid obese subjects
Small mesenteric arteries from NIR-MO did not show
significant differences in the BK-evoked vasodilation when
compared to control non-obese subjects (Figure 1A). By
opposite, a significant reduction in the endothelium-
mediated vasodilation induced by BK was observed in mes-
enteric microvessels obtained from IR-MO group when
compared to those from control or NIR-MO subjects
(Figure 1A). To avoid a potential bias due to the compari-
son of the vascular responses instead of comparing the re-
sponse in the subjects, we confirmed these results assessing
the differences between the pD2 values for BK averaged
from all the vessels from each subject by group (control,
NIR-MO and IR-MO). This approach yielded very similar
results to that observed when we analysed the response of
the vessels. pD2 for BK were 7.23±0.20 (N=12), 7.27±0.11
(N=20) and 6.69±0.14 (N=32) for control, NIR-MO and IR-
MO, respectively (p < 0.01 IR-MO vs. NIR-MO or control
subjects by one-factor ANOVA followed by Student-
Newmann-Keuls).
Accordingly, the in vitro vasorelaxant response to BK
in microarteries derived from MO subjects decreased as
the HOMA-IR index increased with a clear correlation
between the HOMA-IR index and the BK pD2 values
(Figure 1B). Furthermore, among all factor studied (Age,
BMI, waist circumference, fasting glucose, HbA1C, total
cholesterol (TC), HDL and LDL-cholesterol, TC/HDL
ratio, triglycerides, CRP and HOMA-IR), only HOMA-
IR (p= 0.017) was associated to BK pD2 values.
The addition of insulin (0.01 nmol/l to 3 μmol/l) to the
organ bath evoked a very weak relaxation in isolated
mesenteric arteries derived from obese and control subjects
and no differences were observed among those subjects
(Emax: 16.0%±10.5 vs 11.2%±3.0 and vs 12.5%±3.2 for
control, NIR-MO and IR-MO subjects, respectively; p=n.s.).
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dependent relaxations evoked by SNP in vessels from
IR-MO people as compared with NIR-MO subjects (pD2
5.59±0.19 vs 4.96±0.25 and vs 5.10±0.30 for control,
NIR-MO and IR-MO subjects, respectively; p=n.s.).
Oxidative stress contributes to endothelial dysfunction in
IR-MO subjects
The contribution of superoxide anions to endothelial dys-
function in IR-MO subjects was confirmed. Preincubation
of the microarteries from these subjects with the
superoxide scavenger, SOD (100 U/ml), improved the
endothelial-dependent relaxation to BK (Figure 1C), while
it did not modify the responses to BK in vessels from NIR-
MO subjects.
With respect to the possible sources of superoxide
production, the roles of NADPH oxidase, NOS uncoupling
and mitochondria were analyzed. The NADPH oxidase in-
hibitor, apocynin (100 μmol/l) did not significantly modifyFigure 1 Insulin resistance is related to endothelial dysfunction in mo
segments derived from control subjects, non-insulin resistant (NIR-MO) and
mean±SEM of the percentage of the contraction elicited by K+. N= the num
NIR-MO and ¶p< 0.001 vs control subjects by two-factors ANOVA. (B) Nega
Resistance (HOMA-IR) score and pD2 values for BK. Each point represents th
of preincubation with the superoxide dismutase (SOD; 100 U/ml) on the re
IR-MO subjects by two-factors ANOVA.BK-induced relaxations in mesenteric microvessels from
IR-MO subjects (Figure 2A). Similar results were obtained
when using the novel specific NADPH oxidase inhibitor,
VAS-2870 (10 μmol/l) (Figure 2B). The NOS cofactor,
tetrahydrobiopterin (BH4, 10 μmol/l) also failed to improve
BK-induced vasodilations in arteries from IR-MO subjects
(Figure 2C). In contrast, the SOD mimetic targeted to the
mitochondria, mito-TEMPO (5 μmol/l), caused a signifi-
cant improvement of endothelium-dependent vasodilation
of arteries from IR-MO subjects (Figure 2D). None of these
treatments modified the vasodilatations to BK in
microvessels derived from NIR-MO (pD2: 7.03±0.55 vs.
7.07±0.43; 7.01±0.06 vs. 7.33±0.20; 7.20±0.31 vs. 6.89±0.42;
7.00±0.41 vs. 6.98±0.29) for VAS-2870, apocynin, BH4, and
mito-TEMPO, respectively).
Consistently, superoxide production, assessed by DHE
fluorescence, was clearly appreciated in vascular wall
sections from IR-MO subjects, while the fluorescence
signal was very weak or absent in vessels from NIR-MOrbid obesity. (A) Vasodilation to bradykinin (BK) in mesenteric arterial
insulin resistant morbid obese (IR-MO) subjects. Data are expressed as
ber of subjects/ n= the number of vascular segments. *p< 0.001 vs
tive correlation between Homeostasis Model Assessment of Insulin
e averaged pD2 values of segments from one single subject. (C) Effect
laxant responses to BK in mesenteric arteries from IR-MO. *p< 0.05 vs
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tion of staining revealed a significant increase in super-
oxide production in arteries from IR-MO with respect to
the other two groups (Figure 3B). In fact, superoxide
generation negatively correlated with pD2 for BK in mes-
enteric microvessels (Figure 3C). Furthermore, the im-
provement of endothelium-dependent vasodilation with
mito-TEMPO was accompanied by a significant reduc-
tion of superoxide generation in arterial wall from IR-
MO subjects (Figure 3A-B).
Inflammatory cytokine, TNF-α, participates in the
impairment of endothelial vasodilation in IR-MO subjects
In mesenteric arteries derived from IR-MO subjects,
neither iNOS selective inhibitor 1400W (10 μmol/l)
(Figure 4A), nor the cyclooxygenase inhibitor indometh-
acin (10 μmol/l) (Figure 4B) modified the impaired
endothelial function observed in these subjects. By con-
trast, the anti-TNF-α, infliximab (100 μmol/l), improvedFigure 2 Sources of superoxide anions in mesenteric arteries of morb
preincubation with the NADPH oxidase inhibitors, apocynin (100 μmol/l) (A
(BH4; 10 μmol/l) (C); and the SOD mimetic targeted to the mitochondria, m
isolated mesenteric microvessels from IR-MO subjects. Data are expressed a
N= the number of subjects/n= the number of vascular segments. *p< 0.00the relaxation to BK in arteries from IR-MO subjects
(Figure 4C). Interestingly, TNF-α blockade with infliximab
also resulted in decreased generation of superoxide in these
arteries (Figure 3A-B). None of those three compounds
had any effect on endothelium-dependent vasodilation
in microvessels derived from NIR-MO (pD2 for BK:
7.67±0.26 vs. 7.57±0.48, 7.23±0.29 vs. 7.00±0.55 and
7.47±0.26 vs. 7.59±0.01, for 1400W, indomethacin and
infliximab, respectively).
Discussion
The main finding of the present study is that endothelial
dysfunction is present only in vessels from obese people
with insulin resistance, suggesting that the association
between morbid obesity and endothelial dysfunction is
linked to the presence of insulin resistance. Such alter-
ation is mediated by increased mitochondrial oxidative
stress and by systemic pro-inflammatory cytokines
(mainly TNF-α). The presence of other cardiovascularid obese subjects with insulin resistance (IR-MO). Effects of
); or VAS2870 (10 μmol/l) (B); the NOS cofactor, tetrahydrobiopterin
ito-TEMPO (5 μmol/l) (D) on the relaxant response to bradykinin in
s mean±SEM of the percentage of the contraction elicited by K+.
1 vs IR-MO by two-factors ANOVA.
Figure 3 Detection of superoxide generation in vessel segments from morbid obese subjects without insulin resistance (NIR-MO) and
with insulin resistance (IR-MO) and the effect of mitochondria antioxidant, mito-TEMPO and the anti-TNF-α, infliximab on superoxide
generation in IR-MO microarteries. Representative photomicrographs (A) and quantitative analysis (B) of the staining (red signal) with the
superoxide-detecting fluorescent probe, dihydroethidium (DHE), in mesenteric microvessels derived from control, NIR-MO and IR-MO subjects
treated or not with the superoxide scavenger targeted to the mitochondria, mito-TEMPO (5 μmol/l), and the anti-TNF-α, infliximab (100 μmol/l)
on superoxide generation in IR-MO vessels. Original magnification is (20X). *p< 0.001 vs control subjects; p < 0.01 vs NIR-MO subjects; † p< 0.05 vs
IR-MO subjects respectively. Each column represents the mean±SEM of 4 to 6 experiments. Panel (C) shows the correlation between the
percentages of DHE positive nuclei and pD2 values for BK.
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to explain the impact of IR on endothelial function in
MO subjects, since no significant differences were
observed between both groups of obese subjects. In
addition, only insulin resistance (HOMA-IR) remained
associated with endothelial function in obese subjects
after adjustment.
Furthermore, endothelial dysfunction associated to in-
sulin resistance in obese subjects does not seem to rely
on a defective vasodilatory action of insulin since, in
contrast to BK-induced responses, insulin-induced vaso-
dilatory responses were not different between MO
subjects with or without IR.
To our knowledge this is the first study describing this
phenomenon in human beings, although recent results
obtained in the microcirculation of obese mice support
our hypothesis [19]. Other previous studies had sug-
gested a relationship between endothelial function and
insulin, HOMA-IR and triglycerides in obese subjects
[20] but without establishing a clear causal relationship
since the design of the study did not allow for
comparing people with insulin-resistance versus people
without insulin-resistance. Supporting our findings thereis another study showing that IR and not BMI is the
major determinant in the impairment of flow mediated
dilation in morbid obese subjects [21]. In this sense, an
improvement of the endothelial function after weight
reduction in obese patients correlates with reduction in
HOMA index rather than with reduction in body
weight [22].
Although not reaching statistical significance, a
larger percentage of IR-MO subjects were taking
hypoglycemiants, being the vast majority metformin
and pioglitazone. It is unlikely that this fact could have
influence on the impaired endothelial dysfunction in
IR-MO group since these agents have been reported to
even improve endothelial vasodilation [23]. Even more,
to discard a possible bias in the results due to the in-
clusion of twelve patients with the diagnosis of type 2
diabetes in the group of IR-MO patients, we made add-
itional analysis of the data after excluding diabetic pa-
tients. The differences between the groups (NIR-MO
and IR-MO) remained without changes. Furthermore,
when diabetic type 2 patients were excluded, the
HOMA-IR still significantly correlated with poorer
BK-induced vasodilation, therefore reinforcing the
Figure 4 Role of inflammation on endothelial dysfunction in morbid obese subjects with insulin resistance (IR-MO). Effects of
preincubation with the iNOS inhibitor, 1400W (10 μmol/l) (A), the COX inhibitor, indomethacin (10 μmol/l) (B), and the anti-TNF-α, infliximab (100
μmol/l) (C) on the relaxant response to bradykinin (BK) in isolated mesenteric microvessels from IR-MO. Data are expressed as mean±SEM of the
percentage of the contraction elicited by K+. N= the number of subjects/n= the number of vascular segments. *p< 0.05 vs IR-MO subjects by
two-factors ANOVA.
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terminant of endothelial dysfunction in obese subjects
independently of the presence of diabetes. In addition, the
percentage of metabolic syndrome is more frequent in IR-
MO when compared to NIR-MO subjects, supporting the
correct classification of the patients.
Several pathophysiological mechanisms are possibly
involved in the interactions among obesity, insulin re-
sistance and endothelial dysfunction [24]. In this sense,
microarteries from IR-MO subjects generate higher
amounts of intravascular ROS than those from NIR-MO
or control subjects, as demonstrated by DHE staining. In
fact, the superoxide scavenger, SOD, caused a significant
improvement of endothelium-dependent relaxation only
in mesenteric arteries from IR-MO subjects, suggesting
that increased superoxide production contributes toendothelial dysfunction in IR-MO vessels by reducing
NO availability. The involvement of superoxide excess in
endothelial dysfunction in obesity is supported by dem-
onstration of increased vascular superoxide generation
in obese subjects [25] and in animal models of obesity
[26] and by the potentiating effect of superoxide
scavengers on ACh-induced relaxations in aortic and
mesenteric arteries from obese animals [27,28] and in
mesenteric microarteries from obese patients [25]. Once
again, these studies did not establish differences based
on the presence or absence of insulin resistance. Present
results suggest that increased superoxide production and
subsequent NO inactivation is associated to IR rather
than to obesity itself, since elevated vascular superoxide
generation and improving vasodilation in response to
SOD are not detected in obese subjects without IR, who
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they have a BMI similar to those with IR.
Several sources of ROS could contribute to the in-
creased superoxide production in the vasculature of
IR-MO subjects. In contrast to that observed in the vas-
culature of obese subjects in other studies [25], we did
not find evidence for the possible implication of NADPH
oxidase since its inhibitors, apocynin and VAS2870, did
not improve endothelial vasodilation in mesenteric
microarteries from IR-MO subjects. NOS uncoupling
can also act as an endothelial source of superoxide. Re-
duced availability of its cofactor, BH4, in pro-oxidant
conditions has been proposed as a mechanism respon-
sible for eNOS uncoupling [29]. The failure of BH4 to
modify vasodilatations suggests that this does not ac-
count for the reduced NO availability associated to IR in
MO subjects. The improvement of endothelial vasodila-
tion caused by the mitochondria-targeted superoxide
scavenger, mito-TEMPO, in vessels from IR-MO sub-
jects suggests that the origin of the impaired NO-
mediated responses in IR associated with obesity is an
increased mitochondrial superoxide production that
limits NO availability. Mito-TEMPO has been demon-
strated to specifically scavenge mitochondrial superoxide in
endothelial cells and vascular tissue [30,31]. Mitochondria
is considered the major intracellular site of superoxide pro-
duction generated from electron leaks in the mitochondrial
electron transport system [32]. When metabolic alterations
lead to inefficient nutrient oxidation, mitochondria in-
creases the production of superoxide and other ROS [32].
There is substantial evidence proposing the importance of
these mitochondrial ROS in the pathophysiology of the vas-
cular damage linked to diabetes and insulin resistance [33].
In fact, clinical evidence has associated insulin resistance
with mitochondrial dysfunction [34,35]. Although it is diffi-
cult to ascertain whether defects in mitochondria occur be-
fore or after the onset of insulin resistance [33], it has been
demonstrated that induction of mitochondrial superoxide
production results in insulin resistant adipocytes [36].
On the other hand, the elevated levels of CRP and the
pro-inflammatory cytokines, TNF-α and IL-6, reflect the
presence of low-grade inflammation in obese subjects
with IR that could contribute to endothelial dysfunction.
In this sense, IL-6 and TNF-α have been demonstrated
to impair endothelial dilation [37,38]. Furthermore, the
effects produced by infliximab on endothelial vasodila-
tation in obese subjects, only when IR is present, sug-
gest a causal role of inflammatory cytokines, TNF-α at
least, in the endothelial impairment exhibited by the
vessels from these subjects. Previous evidences show-
ing that blockade of TNF-α with infliximab results in
the recovery of impaired endothelial vasodilation in
omental vessels from obese subjects [25] support this
hypothesis. CRP levels did not show any correlationwith pD2, although we cannot definitively exclude its
participation.
The impact of systemic inflammatory cytokines in
endothelial dysfunction does not seem to be mediated
by up-regulation of conventional local inflammatory
pathways, since both inhibitors of iNOS and COX did
not improve endothelial relaxation. Deleterious effects of
pro-inflammatory cytokines on endothelial function in
obese patients could be also mediated by oxidative
stress generation since these effects can be reversed by
superoxide scavengers [25,39]. Furthermore, exposure to
TNF-α stimulates mitochondrial superoxide production
in mouse adipocytes [36] and human retinal endothelial
cells [40]. This is consistent with the reduction of super-
oxide production observed in arteries from IR-MO sub-
jects after the treatment with infliximab. Thus, systemic
inflammation and mitochondrial superoxide production
could be two closely related or even interdependent
mechanisms mediating endothelial dysfunction in insulin
resistance associated with obesity.
Obese subjects exhibit increased circulating levels of
pro-inflammatory resistin and decreased levels of the
anti-inflammatory cytokine, adiponectin, irrespective of
the state of IR, which is in agreement with previous
studies done in obese patients [41]. Then, increased
adiposity is associated with adipose tissue inflammation
and dysregulation of adipokines but this condition is
related to obesity per se independently of the insulin
resistance state, and, therefore, it does not seem to be de-
terminant for the development of endothelial dysfunction.
We recognize that one limitation of the study is that
vascular function has been evaluated in subjects with se-
vere obesity so caution is required when any extrapola-
tion from the present is made to overweight or non-
severe obese subjects. Another potential limitation is
that the present findings have been achieved based on
an in vitro approach where endothelial function has
been assessed in isolated microarteries segments. There-
fore further in vivo studies (carotid artery ultrasound
and/or endo-peripheral arterial tone) are needed to con-
firm our findings. However, a recent study showing
in vivo a strong dependence of endothelial dysfunction
on insulin resistance in obese individuals supports our
findings [21].
Conclusions
The present results reveal the determinant role of insulin
resistance in the impairment of endothelium-dependent
vasodilation in morbid obese patients. Endothelial dysfunc-
tion is produced by means of a reduced NO availability as a
result of increased vascular superoxide generation by mito-
chondria. Moreover, the inflammatory mediator TNF-α
contributes to the impaired vasodilation associated to IR in
obese subjects. These findings may help to explain the link
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targets for specific intervention aimed at delaying or
preventing the appearance of vascular disease.
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